<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genomics</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med Genomics</journal-id><journal-title-group><journal-title>BMC Medical Genomics</journal-title></journal-title-group><issn pub-type="epub">1755-8794</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5069826</article-id><article-id pub-id-type="publisher-id">225</article-id><article-id pub-id-type="doi">10.1186/s12920-016-0225-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Technical Advance</subject></subj-group></article-categories><title-group><article-title>Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Omolo</surname><given-names>Bernard</given-names></name><address><email>bomolo@uscupstate.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Yang</surname><given-names>Mingli</given-names></name><address><email>myang@gibbscc.org</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lo</surname><given-names>Fang Yin</given-names></name><address><email>Fangyin.Lo@covance.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Schell</surname><given-names>Michael J.</given-names></name><address><email>michael.schell@moffitt.org</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Austin</surname><given-names>Sharon</given-names></name><address><email>Sharon.Austin@covance.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Howard</surname><given-names>Kellie</given-names></name><address><email>kellie.howard@covance.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Madan</surname><given-names>Anup</given-names></name><address><email>Anup.Madan@covance.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yeatman</surname><given-names>Timothy J.</given-names></name><address><phone>864-560-1052</phone><email>yeatman@gibbscc.org</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Division of Mathematics and Computer Science, University of South Carolina-Upstate, 800 University Way, Spartanburg, SC 29303 USA </aff><aff id="Aff2"><label>2</label>Gibbs Cancer Center and Research Institute, 101 E Wood Street, Spartanburg, SC 29303 USA </aff><aff id="Aff3"><label>3</label>Genomic Services, Covance Genomics Lab, 9911 Willows Road, Suite 175, Redmond, WA 98052 USA </aff><aff id="Aff4"><label>4</label>Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612 USA </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>9</volume><elocation-id>65</elocation-id><history><date date-type="received"><day>28</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>7</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>The <italic>KRAS</italic> gene is mutated in about 40&#x000a0;% of colorectal cancer (CRC) cases, which has been clinically validated as a predictive mutational marker of intrinsic resistance to anti-EGFR inhibitor (EGFRi) therapy. Since nearly 60&#x000a0;% of patients with a wild type <italic>KRAS</italic> fail to respond to EGFRi combination therapies, there is a need to develop more reliable molecular signatures to better predict response. Here we address the challenge of adapting a gene expression signature predictive of RAS pathway activation, created using fresh frozen (FF) tissues, for use with more widely available formalin fixed paraffin-embedded (FFPE) tissues.</p></sec><sec><title>Methods</title><p>In this study, we evaluated the translation of an 18-gene RAS pathway signature score from FF to FFPE in 54 CRC cases, using a head-to-head comparison of five technology platforms. FFPE-based technologies included the Affymetrix GeneChip (Affy), NanoString nCounter&#x02122; (NanoS), Illumina whole genome RNASeq (RNA-Acc), Illumina targeted RNASeq (t-RNA), and Illumina stranded Total RNA-rRNA-depletion (rRNA).</p></sec><sec><title>Results</title><p>Using Affy_FF as the &#x0201c;gold&#x0201d; standard, initial analysis of the 18-gene RAS scores on all 54 samples shows varying pairwise Spearman correlations, with (1) Affy_FFPE (<italic>r&#x02009;=</italic>&#x02009;0.233, <italic>p</italic>&#x02009;=&#x02009;0.090); (2) NanoS_FFPE (<italic>r&#x02009;=</italic>&#x02009;0.608, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001); (3) RNA-Acc_FFPE (<italic>r&#x02009;=</italic>&#x02009;0.175, <italic>p</italic>&#x02009;=&#x02009;0.21); (4) t-RNA_FFPE (<italic>r&#x02009;=</italic>&#x02009;&#x02212;0.237, <italic>p</italic>&#x02009;=&#x02009;0.085); (5) and t-RNA (<italic>r&#x02009;=</italic>&#x02009;&#x02212;0.012, <italic>p</italic>&#x02009;=&#x02009;0.93). These results suggest that only NanoString has successful FF to FFPE translation. The subsequent removal of identified &#x0201c;problematic&#x0201d; samples (<italic>n&#x02009;=</italic>&#x02009;15) and genes (<italic>n&#x02009;=</italic>&#x02009;2) further improves the correlations of Affy_FF with three of the five technologies: Affy_FFPE (<italic>r&#x02009;=</italic>&#x02009;0.672, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001); NanoS_FFPE (<italic>r&#x02009;=</italic>&#x02009;0.738, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001); and RNA-Acc_FFPE (<italic>r&#x02009;=</italic>&#x02009;0.483, <italic>p</italic>&#x02009;=&#x02009;0.002).</p></sec><sec><title>Conclusions</title><p>Of the five technology platforms tested, NanoString technology provides a more faithful translation of the RAS pathway gene expression signature from FF to FFPE than the Affymetrix GeneChip and multiple RNASeq technologies. Moreover, NanoString was the most forgiving technology in the analysis of samples with presumably poor RNA quality. Using this approach, the RAS signature score may now be reasonably applied to FFPE clinical samples.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12920-016-0225-2) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Colorectal cancer</kwd><kwd>FF (fresh-frozen)</kwd><kwd>FFPE (formalin-fixed</kwd><kwd>Paraffin embedded)</kwd><kwd>Microarray</kwd><kwd>NanoString</kwd><kwd>RAS pathway signature</kwd><kwd>RNASeq</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>U01CA157960</award-id><principal-award-recipient><name><surname>Yeatman</surname><given-names>Timothy J.</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>The Burroughs Wellcome Fund</institution></funding-source><award-id>1015192</award-id><principal-award-recipient><name><surname>Omolo</surname><given-names>Bernard</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000893</institution-id><institution>Simons Foundation</institution></institution-wrap></funding-source><award-id>282714</award-id><principal-award-recipient><name><surname>Omolo</surname><given-names>Bernard</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Colorectal cancer (CRC) is the third most common cancer in men and women [<xref ref-type="bibr" rid="CR1">1</xref>]. Nearly one-third of the patients will eventually die of the disease. Hyperactivation of the RAS signaling pathway is a driver of many cancers, including CRC [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Activating mutations in the K-ras proto-oncogene (<italic>KRAS</italic>) are found in approximately 40&#x000a0;% of colorectal tumors [<xref ref-type="bibr" rid="CR4">4</xref>]. Thus, the RAS pathway activation has become a major focus of drug targeting efforts, including prediction of response to targeted therapies [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. For example, the epidermal growth factor receptor (EGFR) is a major therapeutic target in metastatic colorectal cancer [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. The fact that nearly 60&#x000a0;% of patients with a wild type <italic>KRAS</italic> fail to respond to combination therapies involving EGFRi [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], however, strongly suggests that there are additional genes, beyond <italic>KRAS</italic>, that contribute to RAS pathway activation. It has been recently reported that mutations in <italic>BRAF</italic> and <italic>NRAS</italic> that also activate the RAS pathway may account for EGFRi therapy resistance in some of the wild-type <italic>KRAS</italic> CRCs [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p><p>A number of gene expression signatures have been developed using multiple types of cancer cell lines and human fresh frozen (FF) samples to predict RAS pathway dependence in association with drug response [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. For example, a 147-gene RAS pathway signature has been reported to be superior to <italic>KRAS</italic> mutation status alone for the prediction of dependence on RAS signaling, and it could predict response to PI3K and RAS pathway inhibitors in lung and breast tumors [<xref ref-type="bibr" rid="CR3">3</xref>]. Low RAS pathway signature score was associated with a higher cetuximab response rates in a retrospective analysis of metastatic CRC [<xref ref-type="bibr" rid="CR3">3</xref>]. Another RAS pathway signature (18 genes) was developed from multiple types of cancer cell lines and human tumors, including CRC, to specifically assess MEK functional output and activation of the RAS/RAF/MEK/ERK pathway [<xref ref-type="bibr" rid="CR2">2</xref>]. While measuring mutations in individual genes such as <italic>KRAS</italic> and <italic>NRAS</italic> can predict EGFRi response, their level of accuracy is low with up to 60&#x000a0;% of patients still not-responding [<xref ref-type="bibr" rid="CR15">15</xref>]. For this reason, multi-gene expression signatures hold promise in being able to more robustly assess pathway activation than single gene mutations, and thus there is an interest in translating them for use with FFPE clinical samples.</p><p>One of the challenges in using these gene expression signature scores is that many have been developed using fresh-frozen (FF) tissues on the Affymetrix GeneChip (microarray) platform. In order for these signature scores to be clinically useful, they need to be adapted to the more commonly available archival formalin-fixed paraffin-embedded (FFPE) tissues [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. However, microarrays that can assess thousands of transcripts are not only expensive but also lack reproducibility, especially when evaluating FFPE samples having low RNA quality [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Determinants of RNA quality from FFPE samples have been reported to include storage time and conditions, fixation time and specimen size [<xref ref-type="bibr" rid="CR20">20</xref>]. RT-qPCR and NanoString technologies have been reported to be useful for gene expression quantification in FFPE tissues [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. However, the recently developed, probe-based NanoString method was shown to be superior to the RT-qPCR approach in archived FFPE samples [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p>To date, the RAS pathway signatures developed in FF samples for prediction of drug response have not been validated in CRC using FFPE samples. Thus, in this study, we elected to evaluate the translation of an 18-gene RAS signature score [<xref ref-type="bibr" rid="CR2">2</xref>] from FF to FFPE in 54 selected CRC cases in a head-to-head comparison of five technology platforms: Affymetrix GeneChip (Affy), NanoString nCounter&#x02122; (NanoS), whole genome RNASeq (Illumina RNA-Access (RNA-Acc), targeted RNASeq (t-RNA), and Illumina Total stranded RNA-rRNA-depletion (rRNA).</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Tissue sample selection</title><p>Fifty-four (54) FFPE evaluable tumor specimens were selected from a larger multi-center cohort of 468 well-characterized colorectal adenocarcinoma patients whose tissues were obtained between October 2006 and September 2010 [<xref ref-type="bibr" rid="CR24">24</xref>]. In all cases, tissue and clinical data were collected on patients with the University of South Florida institutional review board approval [<xref ref-type="bibr" rid="CR25">25</xref>]. All tumors were collected from curative survival resections and snap frozen in liquid nitrogen within 15&#x02013;20&#x000a0;min of extirpation. The sample cohort was composed of tumor samples that were available as matched fresh-frozen (FF) and formalin-fixed paraffin-embedded (FFPE) pairs. As shown in Additional file <xref rid="MOESM1" ref-type="media">1</xref>, the 54 samples had mutant <italic>KRAS</italic> (25/54 or 46&#x000a0;%) and <italic>BRAF</italic> (2/54 or 4&#x000a0;%), but no <italic>NRAS</italic> mutations.</p><p>The Affymetrix GeneChip, NanoString, whole genome RNASeq, and targeted RNASeq assays on the 54 FFPE samples were performed at LabCorp, Inc., Seattle, USA. Whole genome RNASeq was further comprised of two library preparation methods: Illumina RNA-Access (RNA-Acc) and Illumina Total stranded RNA-rRNA-depletion (rRNA), which were analyzed as separate datasets. Targeted RNA sequencing data (t-RNA) was based on the RAS 18-gene signature [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p>The flowchart (see Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) below shows the steps followed in the pre-processing and analysis of the data. The statistical methods used include [<xref ref-type="bibr" rid="CR1">1</xref>] the Robust Microarray Average (RMA) method [<xref ref-type="bibr" rid="CR26">26</xref>] for the normalization of Affy_FF and Affy_FFPE samples; [<xref ref-type="bibr" rid="CR2">2</xref>] principal component analysis (PCA) [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR27">27</xref>] to identify &#x0201c;bad&#x0201d; samples from the Affy_FFPE data; [<xref ref-type="bibr" rid="CR3">3</xref>] correlation analyses among the datasets; and [<xref ref-type="bibr" rid="CR4">4</xref>] the nearest shrunken centroids algorithm for predicting the mutation type of a sample.<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow-chart of the procedure followed in the pre-processing and analysis of the data. Six datasets (1 FF and 5 FFPE, each with 54 samples and 18 genes) underwent quality control procedures before analysis. Thirty-nine [<xref ref-type="bibr" rid="CR39">39</xref>] &#x0201c;good&#x0201d; samples and 16 &#x0201c;good&#x0201d; genes were retained. Correlation analyses were performed using mean scores from the sample pairs. The predictive ability of the 16&#x02013;gene set was validated using the Affymetrix FF, Affymetrix FFPE and NanoString gene expression data, by the PAM method</p></caption><graphic xlink:href="12920_2016_225_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec4"><title>Data pre-processing</title><p>Both the 54 Affy_FF and matching Affy_FFPE samples were normalized using the RMA method [<xref ref-type="bibr" rid="CR26">26</xref>]. For the NanoString data, we used the reference (housekeeping) gene normalization method, as described in the nCounter&#x000ae; Expression Data Analysis Guide (available at <ext-link ext-link-type="uri" xlink:href="http://www.nanostring.com/media/pdf/MAN_nCounter_Gene_Expression_Data_Analysis_Guidelines.pdf">http://www.nanostring.com/media/pdf/MAN_nCounter_Gene_Expression_Data_Analysis_Guidelines.pdf</ext-link>). The 11 housekeeping genes were <italic>BIRC6, EMC8, HADHA, MAEA, MRPL18, ORMDL1, PSMD11, RBM4, STX6, TRIM39</italic>, and <italic>UBE2K</italic>. The geometric mean of these reference genes was obtained for each sample (lane) and the average of these means across all samples calculated. The normalization factor for each sample was the overall mean divided by the geometric mean. We multiplied this factor by the mRNA transcript count for each of the 18 RAS genes in the sample. For the targeted RNA data, we used median normalization. For that platform, we obtained the median for each of the samples and subtracted this number from each of the gene counts for the sample. Notably, global normalization using median-centering is commonly used to correct for sample-specific bias (due to experimental artefacts) and render the gene expression levels comparable in differential gene expression analysis in microarrays [<xref ref-type="bibr" rid="CR28">28</xref>]. With the advent of RNASeq technology, the method has been adopted to render counts from different samples, which may have been sequenced to different depths, comparable [<xref ref-type="bibr" rid="CR29">29</xref>]. Thus, gene expression values could be positive or negative numbers relative to a reference (e.g. median). For the whole transcriptome RNASeq (RNA-Acc and rRNA) platforms, the data was first processed by STAR aligner [<xref ref-type="bibr" rid="CR30">30</xref>] and cufflinks [<xref ref-type="bibr" rid="CR31">31</xref>], then the resulting FPKM was log2-transformed and z-score-normalized.</p></sec><sec id="Sec5"><title>Probe filtration</title><p>After normalization, filtration of probes was performed for both the Affy_FF and Affy_FFPE data. Probes were retained if they had at least 1.5-fold change in either direction of the median expression level in at least 20&#x000a0;% of the samples and if they had at most 50&#x000a0;% missing values across the samples. The entire probe filtration process was implemented by the BRB-ArrayTools software [<xref ref-type="bibr" rid="CR32">32</xref>]. The NanoS_FFPE, RNA-Acc_FFPE, t-RNA and rRNA_FFPE datasets did not have probe-level data and so were not subjected to the probe filtration process.</p></sec><sec id="Sec6"><title>Calculation of RAS pathway activation scores before probe filtration</title><p>The next step was to calculate the RAS pathway activation scores from the normalized 54 Affy_FF and Affy_FFPE samples. For genes with multiple probes/probesets in the dataset, probes/probesets from the same gene were averaged to yield one value of the expression level for each gene. The mean of these expression levels across the 18 RAS genes was calculated for each sample to yield the sample mean score. The sample mean scores for the NanoS_FFPE, RNA-Acc_FFPE, t-RNA_FFPE and rRNA_FFPE were obtained by averaging across the 18 RAS genes.</p></sec><sec id="Sec7"><title>Calculation of RAS pathway activation scores after probe filtration</title><p>The probe filtration resulted in a reduction of probes from 60,607 to 23,765. Some genes that were represented by only one probe in the dataset were filtered out in this filtration process. For the remaining genes with multiple probes/probesets, the probes/probesets were reduced to one per gene by selecting the probe with the highest mean signal strength across the samples. The mean expression levels across the remaining 16 RAS genes were calculated for each sample to yield the sample mean score. The sample mean scores for the NanoS_FFPE, RNA-Acc_FFPE, t-RNA_FFPE and rRNA_FFPE were obtained by averaging across the 16 RAS genes.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p>The FF - FFPE sample pairs of mean scores were used in the correlation analyses, using SAS software version 9.4 (SAS Institute, Cary, NC, USA). There were 15 possible combinations of the sample pairs, among the six datasets (Affy_FF, Affy_FFPE, NanoS_FFPE, RNA-Acc_FFPE, t-RNA-FFPE, and rRNA_FFPE), yielding 15 pairwise Spearman correlations. We also assessed the effect of removing &#x0201c;bad&#x0201d; samples and probes on the Spearman correlations across the five platforms. To identify the &#x0201c;bad&#x0201d; samples, we performed a principal component analysis (PCA) of the 54 Affy_FFPE samples, with the entire set of 60,607 probes, to generate the first two principal components (PC1 and PC2), using the SAS software version 9.4. The PC1 and PC2 scores were identified as the eigenvectors of the covariance matrix of the 54 Affy_FFPE samples that accounted for the highest and the second-highest variation in the data, respectively. A scatterplot of PC2 vs PC1 was used to show the location of the possibly &#x0201c;bad&#x0201d; samples.</p><p>Samples were classified as either <italic>KRAS</italic>/<italic>BRAF</italic> mutant or <italic>KRAS</italic>/<italic>BRAF</italic> wild-type (WT). The nearest shrunken centroids algorithm [<xref ref-type="bibr" rid="CR33">33</xref>] was employed in predicting the mutation type of a sample, based on the gene expression profiles of the 16 genes from the 18-gene RAS signature. This algorithm was implemented by the Prediction Analysis of Microarrays (PAM) tool in BRB-ArrayTools software [<xref ref-type="bibr" rid="CR32">32</xref>]. The algorithm builds several linear models (classifiers) containing up to 16 genes and selects the model with the minimal prediction error. The prediction error of the models are estimated using leave-one-out cross-validation (LOOCV) as described in [<xref ref-type="bibr" rid="CR34">34</xref>]. For each leave-one-out training set, the entire model building process was repeated, including the gene selection process. The proportion of times when classifiers incorrectly predicted the class (miss-classification rate) of the excluded samples was recorded for the entire training set of samples.</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>NanoString effectively translates the 18 gene RAS scores from FF to FFPE in all 54 samples</title><p>A gene expression RAS pathway signature [<xref ref-type="bibr" rid="CR2">2</xref>], comprised of 18 genes (<italic>DUSP4, DUSP6, ELF1, ETV4, ETV5, FXYD5, KANK1, LGALS3, LZTS1, MAP2K3, PHLDA1, PROS1, S100A6, SERPINB1, SLCO4A, SPRY2, TRIB2</italic> and <italic>ZFP106)</italic>, was used to evaluate FF to FFPE translation on the 54 samples (see Table&#x000a0;<xref rid="Tab1" ref-type="table">1A</xref>). Results show the pairwise Spearman correlations of Affy_FF scores (&#x0201c;gold&#x0201d; standard) with five sets of scores obtained from [<xref ref-type="bibr" rid="CR1">1</xref>] Affy_FFPE; [<xref ref-type="bibr" rid="CR2">2</xref>] NanoS_FFPE; [<xref ref-type="bibr" rid="CR3">3</xref>] RNA-Acc_FFPE; [<xref ref-type="bibr" rid="CR4">4</xref>] t-RNA_FFPE; and [<xref ref-type="bibr" rid="CR5">5</xref>] rRNA_FFPE. Only NanoS_FFPE appeared to have successful FF to FFPE translation for the 18-gene RAS scores (<italic>r&#x02009;=</italic>&#x02009;0.608, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) when all samples were utilized. Notably, among the five FFPE technology platforms, pairwise correlations between Affy_FFPE and each of NanoS_FFPE, RNA-Acc_FFPE and t-RNA_FFPE were significant.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Spearman correlations for the 18-gene RAS signature scores among six datasets, including Affy_FF, NanoS_FFPE, RNA-Acc_FFPE, t-RNA_FFPE, and rRNA_ FFPE on 54 and 39 samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Mean Score</th><th>Affy FF</th><th>Affy FFPE</th><th>NanoS FFPE</th><th>RNA-Acc FFPE</th><th>t-RNA FFPE</th><th>rRNA FFPE</th></tr></thead><tbody><tr><td colspan="7">A. 54 samples</td></tr><tr><td>Affy FF</td><td>1</td><td>0.233 (0.090)</td><td>0.608 (&#x0003c;0.0001)</td><td>0.175 (0.207)</td><td>&#x02212;0.237 (0.085)</td><td>&#x02212;0.012 (0.934)</td></tr><tr><td>Affy FFPE</td><td/><td>1</td><td>0.399 (0.003)</td><td>0.760 (&#x0003c;0.0001)</td><td>0.278 (0.042)</td><td>0.260 (0.058)</td></tr><tr><td>NanoS FFPE</td><td/><td/><td>1</td><td>0.473 (0.0003)</td><td>&#x02212;0.207 (0.134)</td><td>0.033 (0.814)</td></tr><tr><td>RNA-Acc FFPE</td><td/><td/><td/><td>1</td><td>0.262 (0.056)</td><td>0.225 (0.102)</td></tr><tr><td>t-RNA FFPE</td><td/><td/><td/><td/><td>1</td><td>0.142 (0.306)</td></tr><tr><td>rRNA FFPE</td><td/><td/><td/><td/><td/><td>1</td></tr><tr><td colspan="7">B. 39 samples</td></tr><tr><td>Affy FF</td><td>1</td><td>0.556 (0.0002)</td><td>0.631 (&#x0003c;0.0001)</td><td>0.261 (0.109)</td><td>&#x02212;0.287 (0.076)</td><td>0.123 (0.455)</td></tr><tr><td>Affy FFPE</td><td/><td>1</td><td>0.832 (&#x0003c;0.0001)</td><td>0.778 (&#x0003c;0.0001)</td><td>0.006 (0.973)</td><td>0.091 (0.581)</td></tr><tr><td>NanoS FFPE</td><td/><td/><td>1</td><td>0.733 (&#x0003c;0.0001)</td><td>&#x02212;0.177 (0.282)</td><td>0.099 (0.551)</td></tr><tr><td>RNA-Acc FFPE</td><td/><td/><td/><td>1</td><td>0.043 (0.797)</td><td>0.090 (0.587)</td></tr><tr><td>t-RNA FFPE</td><td/><td/><td/><td/><td>1</td><td>&#x02212;0.071 (0.668)</td></tr><tr><td>rRNA FFPE</td><td/><td/><td/><td/><td/><td>1</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec11"><title>Identification and removal of 15 &#x0201c;poor&#x0201d; quality samples improves the FF - FFPE correlations</title><p>Sfakianos et al. used the PCA procedure to detect outliers and showed that the outliers were associated with poor quality samples [<xref ref-type="bibr" rid="CR19">19</xref>]. More recently, Guinney et al. performed quality control analysis for outlier detection using PCA [<xref ref-type="bibr" rid="CR11">11</xref>]. We adopted this procedure to identify samples that could possibly have &#x0201c;poor&#x0201d; RNA quality. A scatterplot (see Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) of the first and second principal component (PC1 and PC2) scores identified fifteen samples with low PC1 scores (hereby less than - 0.10) that were considered to be &#x0201c;outliers&#x0201d;, or samples likely to have &#x0201c;poor&#x0201d; RNA quality. Notably, as compared to other 39 &#x0201c;good&#x0201d; samples (see Table <xref rid="Tab1" ref-type="table">1B</xref>), most of 15 samples identified also had low standard deviations (signal-to-noise ratios) across probes (data not shown). Furthermore, these 15 samples all had below average Affy_FFPE mean scores in contrast to their wide-spread pattern for Affy-FF scores (see Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>). Thus, these data support the notion that low PC1 scores were likely associated with &#x0201c;poor&#x0201d; RNA quality, However, these 15 &#x0201c;bad&#x0201d; samples did not stand out among the NanoS_FFPE mean scores (see Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>), suggesting that NanoString technology may be more forgiving of poor RNA quality inherent to these samples. The 15 samples identified with potential &#x0201c;poor&#x0201d; quality were removed, leaving 39 samples available for subsequent analyses.<fig id="Fig2"><label>Fig. 2</label><caption><p>Scatterplot of the second vs. first principal component (PC2 vs PC1) for the 54 Affymetrix FFPE samples. The 15 &#x0201c;bad&#x0201d; samples (with low PC1 scores) are colored red and were excluded from subsequent analyses. Each sample was labeled using the last 3 digits of its name (barcode)</p></caption><graphic xlink:href="12920_2016_225_Fig2_HTML" id="MO2"/></fig>
<fig id="Fig3"><label>Fig. 3</label><caption><p>Scatterplots of the Affymetrix FF vs. Affymetrix FFPE (<bold>a</bold>) and NanoString FFPE (<bold>b</bold>) mean scores for the 54 samples. The red circles represent the 15 samples with &#x0201c;poor&#x0201d; RNA quality</p></caption><graphic xlink:href="12920_2016_225_Fig3_HTML" id="MO3"/></fig>
</p><p>As shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1B</xref>, the removal of 15 &#x0201c;outlier&#x0201d; samples resulted in increases in three pairwise correlations among Affy_FF vs. [<xref ref-type="bibr" rid="CR1">1</xref>] Affy_FFPE, [<xref ref-type="bibr" rid="CR2">2</xref>] NanoS_FFPE and [<xref ref-type="bibr" rid="CR3">3</xref>] RNA-Acc_FFPE. Notably, the correlation between Affy_FF and Affy_FFPE changed from being insignificant (<italic>r&#x02009;=</italic>&#x02009;0.233, <italic>p</italic>&#x02009;=&#x02009;0.090) to significant (<italic>r&#x02009;=</italic>&#x02009;0.556, <italic>p</italic>&#x02009;=&#x02009;0.0002).</p><p>Notably, while the 39 &#x0201c;good&#x0201d; samples had mutant <italic>KRAS</italic> (19/39) and <italic>BRAF</italic> (1/39), the 15 &#x0201c;bad&#x0201d; samples had mutant <italic>KRAS</italic> (6/15) and <italic>BRAF</italic> (1/15). No signification association was seen between sample RNA quality and <italic>KRAS/BRAF</italic> genotypes. For example, the Fisher&#x02019;s exact test of association of <italic>BRAF</italic> mutation status and sample RNA quality was insignificant (<italic>p</italic>&#x02009;=&#x02009;0.5711). This suggests that the &#x0201c;badness&#x0201d; of the 15 samples is likely not due to a biological reason (e.g. <italic>BRAF</italic> V600E enrichment), but rather&#x0feff; to a &#x0201c;technical aspect of the sample preparation&#x0201d;.</p></sec><sec id="Sec12"><title>Reduction of probes and associated genes in attempt to improve further the FF-FFPE correlations</title><p>The 18 RAS signature genes were represented by 51&#x000a0;probes and 50 probesets, in the Affy_FF and Affy_FFPE datasets, respectively, with 48 probes in common to both. Probe selection was performed to exclude probes that were not sufficiently differentially-expressed across the 39 samples. The selection was performed from the entire set of 60,607 probes on 39 Affy_FFPE samples. We first filtered out those probes with less than 1.5-fold change in either direction of the probe&#x02019;s median value and then filtered out those with at least 1.5 fold change but in less than 20&#x000a0;% of the samples, resulting in 23,765 probes in 10,031 genes. We then reduced the number of probes to one per gene, by selecting the probes with the highest mean expression values. Due to the probe selection, all probes from the genes <italic>LZTS1</italic> and <italic>ZFP106</italic> were dropped, yielding a 16-gene signature that was then applied to the 54 and 39 samples, respectively.</p><p>Removal of 2 &#x0201c;problematic&#x0201d; probes/genes, while retaining all 54 tumors, resulted in a modest increase in two pairwise correlations among Affy_FF vs. [<xref ref-type="bibr" rid="CR1">1</xref>] Affy_FFPE and [<xref ref-type="bibr" rid="CR2">2</xref>] NanoS_FFPE (comparing Table&#x000a0;<xref rid="Tab1" ref-type="table">1A</xref> vs. Table&#x000a0;<xref rid="Tab2" ref-type="table">2A</xref>). Of interest, the performance of t-RNA_FFPE and rRNA_FFPE were also improved with probe reduction.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Spearman correlations for the 16-gene RAS signature scores among six datasets, including Affy_FF, NanoS_FFPE, RNA-Acc_FFPE, rRNA_FFPE, and t-RNA_ FFPE on 54 and 39 samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Mean Score</th><th>AffyFF</th><th>Affy FFPE</th><th>NanoS FFPE</th><th>RNA-Acc FFPE</th><th>t-RNA FFPE</th><th>rRNA FFPE</th></tr></thead><tbody><tr><td colspan="7">A. 54 samples</td></tr><tr><td>Affy FF</td><td>1</td><td>0.300 (0.028)</td><td>0.707 (&#x0003c;0.0001)</td><td>0.264 (0.054)</td><td>&#x02212;0.195 (0.157)</td><td>0.019 (0.890)</td></tr><tr><td>Affy FFPE</td><td/><td>1</td><td>0.361 (0.007)</td><td>0.773 (&#x0003c;0.0001)</td><td>0.296 (0.030)</td><td>0.369 (0.006)</td></tr><tr><td>NanoS FFPE</td><td/><td/><td>1</td><td>0.487 (0.0002)</td><td>&#x02212;0.155 (0.264)</td><td>0.039 (0.779)</td></tr><tr><td>RNA-Acc FFPE</td><td/><td/><td/><td>1</td><td>0.262 (0.056)</td><td>0.295 (0.031)</td></tr><tr><td>t-RNA FFPE</td><td/><td/><td/><td/><td>1</td><td>0.194 (0.159)</td></tr><tr><td>rRNA FFPE</td><td/><td/><td/><td/><td/><td>1</td></tr><tr><td colspan="7">B. 39 samples</td></tr><tr><td>Affy FF</td><td>1</td><td>0.672 (&#x0003c;0.0001)</td><td>0.738 (&#x0003c;0.0001)</td><td>0.483 (0.002)</td><td>&#x02212;0.228 (0.163)</td><td>0.174 (0.290)</td></tr><tr><td>Affy FFPE</td><td/><td>1</td><td>0.845 (&#x0003c;0.0001)</td><td>0.754 (&#x0003c;0.0001)</td><td>0.014 (0.934)</td><td>0.170 (0.301)</td></tr><tr><td>NanoS FFPE</td><td/><td/><td>1</td><td>0.802 (&#x0003c;0.0001)</td><td>&#x02212;0.096 (0.560)</td><td>0.150 (0.361)</td></tr><tr><td>RNA-Acc FFPE</td><td/><td/><td/><td>1</td><td>0.053 (0.750)</td><td>0.182 (0.269)</td></tr><tr><td>t-RNA FFPE</td><td/><td/><td/><td/><td>1</td><td>&#x02212;0.018 (0.915)</td></tr><tr><td>rRNA FFPE</td><td/><td/><td/><td/><td/><td>1</td></tr></tbody></table></table-wrap>
</p><p>Building to improve the model, the removal of both 15 samples and 2 probes/genes further enhanced the correlations of Affy_FF vs. Affy_FFPE, NanoS_FFPE, and RNA-ACC_FFPE (comparing Table&#x000a0;<xref rid="Tab1" ref-type="table">1A</xref> vs. Table&#x000a0;<xref rid="Tab2" ref-type="table">2B</xref>).</p></sec><sec id="Sec13"><title>Using a PAM classifier to predict <italic>KRAS</italic>/<italic>BRAF</italic> mutation status using the 16-gene expression data</title><p>The Affy_FF gene expression score might be considered a new &#x0201c;gold&#x0201d; standard because of its potential capacity to more inclusively identify tumors with RAS pathway activation not necessarily linked to RAS mutation. RAS mutation status, however, taken by itself, could also be considered a &#x0201c;gold&#x0201d; standard, and in fact is the current clinical standard used to qualify the administration of EGRFi therapies. We therefore sought to validate the known mutational status of previously sequenced CRC samples (<italic>n&#x02009;=</italic>&#x02009;54) using our Affy_FF, Affy_FFPE and NanoS_FFPE datasets in conjunction with the modified 16-gene RAS signature score. In this regard, the samples were classified as either <italic>KRAS</italic>/<italic>BRAF</italic> mutant or <italic>KRAS</italic>/<italic>BRAF</italic> wild-type, resulting in two classes. Notably, no <italic>NRAS</italic> mutation was detected in the 54 samples (Additional File <xref rid="MOESM1" ref-type="media">1</xref>). For each dataset, we developed linear models utilizing gene expression profiles of the 16 genes to predict the class (mutation type) of future samples. Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> shows the sensitivity and specificity values for the classifier, together with the LOOCV miss-classification rates. Class prediction was performed using the gene expression data (<italic>n&#x02009;=</italic>&#x02009;54) from the Affy_FF, Affy_FFPE and NanoS_FFPE samples. The 16-gene Affy_FF classifiers performed best in predicting <italic>KRAS</italic>/<italic>BRAF</italic> mutation status (error rate&#x02009;=&#x02009;19&#x000a0;%), with an optimal sensitivity of 0.852 and specificity of 0.778. Reduction in sample size was ineffective in improving <italic>KRAS</italic>/<italic>BRAF</italic> mutation status predictions (results not shown). Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> shows the reduced gene sets in the selected predictive model (one with the minimal error of prediction) for each of the validation datasets (Affy_FF, NanoS_FFPE and Affy_FFPE) out of the 16 genes.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Performance of the 16-gene PAM classifier on the 54 samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Validation dataset</th><th>Class</th><th>Sensitivity<sup>a</sup>
</th><th>Specificity<sup>b</sup>
</th><th>LOOCV error rate</th></tr></thead><tbody><tr><td>Affy FF</td><td>Mut</td><td>0.852&#x02009;=&#x02009;23/27</td><td>0.778&#x02009;=&#x02009;21/27</td><td>19&#x000a0;%</td></tr><tr><td>NanoS_FFPE</td><td>Mut</td><td>0.704&#x02009;=&#x02009;19/27</td><td>0.741&#x02009;=&#x02009;20/27</td><td>28&#x000a0;%</td></tr><tr><td>Affy_FFPE</td><td>Mut</td><td>0.519&#x02009;=&#x02009;14/27</td><td>0.889&#x02009;=&#x02009;24/27</td><td>30&#x000a0;%</td></tr></tbody></table><table-wrap-foot><p>
<italic>Note</italic>: Samples were classified as either <italic>KRAS</italic>/<italic>BRAF</italic> mutant (Mut, <italic>n&#x02009;=</italic>&#x02009;27) or <italic>KRAS</italic>/<italic>BRAF</italic> wild-type (WT, <italic>n&#x02009;=</italic>&#x02009;27). Class prediction was performed using the Affy_FF, Affy_FFPE and NanoS_FFPE samples sets</p><p>
<sup>a</sup>&#x02009;=&#x02009;number of predicted mutants divided by number of true mutants</p><p>
<sup>b</sup>&#x02009;=&#x02009;number of predicted WT divided by number of true WT</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Genes in the predictive models of the 54-tissue PAM analyses</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Validation dataset</th><th colspan="7">Genes</th></tr></thead><tbody><tr><td>Affy_FF</td><td>
<italic>DUSP4</italic>
</td><td>
<italic>DUSP6</italic>
</td><td>
<italic>ETV4</italic>
</td><td>
<italic>ETV5</italic>
</td><td>
<italic>PHLDA1</italic>
</td><td>
<italic>SERPINB1</italic>
</td><td>
<italic>TRIB2</italic>
</td></tr><tr><td>NanoS_FFPE</td><td>
<italic>DUSP4</italic>
</td><td>
<italic>DUSP6</italic>
</td><td/><td>
<italic>ETV5</italic>
</td><td/><td>
<italic>SERPINB1</italic>
</td><td/></tr><tr><td>Affy_FFPE</td><td>
<italic>DUSP4</italic>
</td><td/><td/><td>
<italic>ETV5</italic>
</td><td/><td/><td/></tr></tbody></table><table-wrap-foot><p>
<italic>Note</italic>: <italic>DUSP4</italic> and <italic>ETV5</italic> are the most common genes in the predictive models</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec14" sec-type="discussion"><title>Discussion</title><p>Gene expression signatures have been identified for prediction of RAS pathway dependence and drug response [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. One obstacle to clinical translation is that these signatures were developed using cell lines and fresh frozen (FF) tissues, whereas usually only formalin-fixed, paraffin embedded (FFPE) tissue of lower quality is readily available for clinical use [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. A number of studies have been reported on gene expression quantitation in FFPE samples using FF as a standard, usually employing one or two technologies, including RT-qPCR, NanoString, and/or Affymetrix GeneChip [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>]. In this study, we simultaneously compared five technology platforms: [<xref ref-type="bibr" rid="CR1">1</xref>] Affymetrix GeneChip; [<xref ref-type="bibr" rid="CR2">2</xref>] NanoString; [<xref ref-type="bibr" rid="CR3">3</xref>] Illumina whole genome RNASeq RNA-Access; [<xref ref-type="bibr" rid="CR4">4</xref>] Illumina Total RNA-stranded rRNA-depletion; and [<xref ref-type="bibr" rid="CR5">5</xref>] targeted RNASeq. Analyses of 54 CRC samples were performed in a head-to-head comparison to identify the optimal method(s) for translating the RAS signature score [<xref ref-type="bibr" rid="CR2">2</xref>] to FFPE tissues. For this purpose, we chose to calculate and compare individual tumor composite (multi-gene) scores rather than compare gene-level measurements in order to derive a more robust comparison of available technology platforms. Here, we found that while NanoString technology is the most forgiving in the analysis of samples with poor RNA quality, Affymetrix and RNA-Access may have potential for FF to FFPE translation upon removal of &#x0201c;outlier&#x0201d; samples.</p><p>The poor quality of RNA extracted from FFPE samples is thought to result from fixing procedures that cause RNA cross-linking and from RNA degradation over time in FFPE blocks depending on storage temperature [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref>]. While Lebbe and co-workers used the expression levels of a set of reference genes to construct a statistic for differentiating &#x0201c;bad&#x0201d; melanoma samples from &#x0201c;good&#x0201d; ones [<xref ref-type="bibr" rid="CR36">36</xref>], Sfakianos et al. used PCA analysis to identify &#x0201c;bad&#x0201d; samples in ovarian cancer FFPE samples [<xref ref-type="bibr" rid="CR19">19</xref>]. We adopted the PCA method to identify and filter out 15 &#x0201c;outlier&#x0201d; samples with &#x0201c;poor&#x0201d; RNA quality. The removal of the &#x0201c;outlier&#x0201d; samples improved the correlations of Affy_FF (as a &#x0201c;gold&#x0201d; standard) significantly with Affy_FFPE, but only slightly with NanoS_FFPE; the 15 &#x0201c;outlier&#x0201d; samples identified for the Affy_FFPE platform did not appear to be outliers for NanoS_FFPE. A plausible explanation is that in contrast to Affymetrix and RNASeq technologies, NanoString is a more &#x0201c;direct&#x0201d; technology (hybridization-based) to detect the number of RNA transcripts, so it does not need steps of mRNA reverse-transcription into cDNA and subsequent cDNA amplification. Reverse-transcription and cDNA amplification are known to be sensitive to the RNA quality issue caused by RNA cross-linking in FFPE samples.</p><p>Since multiple different gene-specific probes (used in Affymetrix technologies) may have different sensitivities to the RNA quality of FFPE samples [<xref ref-type="bibr" rid="CR21">21</xref>], we used the mean signal scores for the probes coupled with their fold-change information, to filter out 2 genes that were insufficiently expressed across the 39 samples. Notably, our probe filtration approach here differs from the filtration methods used previously in the literature [<xref ref-type="bibr" rid="CR39">39</xref>]. The removal of these two genes improved the FF to FFPE translation by both Affymetrix and NanoString methods. This indicates that the RNA quality and probe problems are two different confounding factors for the translation of the RAS signature scores. Notably, we observed poor correlations and no significant improvement upon removal of the &#x0201c;outlier&#x0201d; samples and/or &#x0201c;bad&#x0201d; probes for Illumina Total RNA-stranded rRNA-depletion, and targeted RNASeq. However, the cause was not clear.</p><p>Moreover, NanoString mean scores were most significantly and consistently correlated with Affymetrix FF, Affymetrix FFPE and RNA-Access mean scores, in the presence or absence of bad samples and probes. Furthermore, while our data suggest that removing &#x0201c;bad&#x0201d; samples can improve the translation of a test from FF to FFPE tissues in Affymetrix FFPE and RNA-Acces platforms, identifying samples with poor RNA quality is not always an easy and practical task. Within a potential future diagnostic setting, it is impractical to perform a PCA across multiple samples to identify &#x0201c;bad&#x0201d; samples. Even if this were practical, it is far from ideal to exclude patients from diagnostic assessment because their FFPE samples happened to have lower quality RNA than usual. In addition, attempting to identify and remove poor quality samples adds an additional step to any analysis. Thus, due to its lower apparent sensitivity to the RNA quality, NanoString technology is more practically useful in translation from FF to FFPE than are the Affymetrix and RNASeq technologies.</p><p>In the assessment of the predictive ability for <italic>KRAS</italic>/<italic>BRAF</italic> mutation status, the Affymetrix _FF 16-gene classifier produced the lowest misclassification rate (19&#x000a0;%) on the 54 samples. Our PAM analysis could further reduce the modified RAS pathway signature gene set from 16 to 7 genes in the Affy_FF classifier. Whereas all 18 genes were selected for capacity to identify MEK pathway activity independent of tumor genotype, the majority of the selected genes have particularly strong and direct relationships to the RAS/MEK/ERK pathway activation. <italic>DUSP4/6</italic> [<xref ref-type="bibr" rid="CR40">40</xref>] and <italic>PHLDA1</italic> (<italic>TGAD51</italic>) [<xref ref-type="bibr" rid="CR41">41</xref>] are known transcriptional targets of MEK/ERK. <italic>ETV4/5</italic> [<xref ref-type="bibr" rid="CR42">42</xref>] can replace RAS/MAPK pathway activation and <italic>TRIB2</italic> can enhance ERK phosphorylation [<xref ref-type="bibr" rid="CR43">43</xref>]. These relationships point to the strength of the signature genes identified by the algorithms applied to our sample sets. Of interest, <italic>SERPINB1</italic> was retained in Affy_FF and NanoS_FFPE sample sets but appeared to have no direct relationship to RAS pathway activation.</p></sec><sec id="Sec15" sec-type="conclusion"><title>Conclusions</title><p>Of the five technology platforms tested, NanoString technology was more adaptive to the translation of the RAS pathway signature from FF tissues to commonly available FFPE tissues than were the Affymetrix GeneChip and RNASeq technologies. NanoString was the most forgiving FFPE technology in reproducing the &#x0201c;gold&#x0201d; standard analysis on matched FF tissues. NanoString technology appears to rescue samples with poor RNA quality, permitting more samples to be scored. These critical analyses pave the way for a RAS pathway signature score to be used to assess FFPE CRC samples for applications such as prediction of EGFRi response to therapy.</p></sec></body><back><app-group><app id="App1"><sec id="Sec16"><title>Additional file</title><p>
<media position="anchor" xlink:href="12920_2016_225_MOESM1_ESM.xlsx" id="MOESM1"><label>Additional file 1:</label><caption><p>The 18 gene RAS scores, and KRAS/BRAF/NRAS mutation status for 54 CRC samples (15 &#x0201c;bad&#x0201d; samples are in bold; PC1: the first principal component; PC2: the second principal component; 1&#x02009;=&#x02009;mutation present, 0&#x02009;=&#x02009;mutation absent; *&#x02009;=&#x02009;score based on 16 genes) (XLSX 15 kb)</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>AffyFF</term><def><p>Affymetrix FF</p></def></def-item><def-item><term>AffyFFPE</term><def><p>Affymetrix FFPE</p></def></def-item><def-item><term>CRC</term><def><p>Colorectal cancer</p></def></def-item><def-item><term>FF</term><def><p>Fresh-frozen</p></def></def-item><def-item><term>FFPE</term><def><p>Formalin-fixed paraffin-embedded</p></def></def-item><def-item><term>IRON</term><def><p>Iterative rank-order normalization</p></def></def-item><def-item><term>LOOCV</term><def><p>Leave-one-out cross-validation</p></def></def-item><def-item><term>NanoS</term><def><p>NanoString</p></def></def-item><def-item><term>NPV</term><def><p>Negative predictive value</p></def></def-item><def-item><term>PAM</term><def><p>Prediction analysis of microarrays</p></def></def-item><def-item><term>PCA</term><def><p>Principal component analysis</p></def></def-item><def-item><term>PPV</term><def><p>Positive predictive value</p></def></def-item><def-item><term>RMA</term><def><p>Robust microarray average</p></def></def-item><def-item><term>RNA-Acc</term><def><p>RNA-Access</p></def></def-item><def-item><term>rRNA</term><def><p>rRNA-depletion</p></def></def-item><def-item><term>t-RNA</term><def><p>Targeted RNA</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>We thank the patients who provided data and tissue to this study.</p><sec id="FPar1"><title>Funding</title><p>This work was supported by a National Institutes of Health grant U01CA157960 (to TJY and BO), a Burroughs Wellcome Fund grant 1015192 (to BO) and a Simons Foundation grant 282714 (to BO).</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>The datasets (the Affymetrix GeneChip, NanoString and RNASeq data) supporting the results of this article have been deposited to the public repository (GEO) under the series accession number GSE86566. The individual datasets are accessible under the accession number GSE86557 for Affy_FF, GSE86559 for Affy_FFPE, GSE86561 for NanoS_FFPE, GSE86562 for RNA-Acc_FFPE, GSE86563 for t-RNA_FFPE, and GSE86564 for rRNA_FFPE.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>BO, MY, FYL, MJS, SA, KH, AM, and TJY performed experiments and analyzed data. BO, MY, MJS, and TJ wrote the manuscript. TJY supervised the project. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declared that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>Tissue and clinical data were collected on patients with the University of South Florida institutional review board approval.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dry</surname><given-names>JR</given-names></name><name><surname>Pavey</surname><given-names>S</given-names></name><name><surname>Pratilas</surname><given-names>CA</given-names></name><name><surname>Harbron</surname><given-names>C</given-names></name><name><surname>Runswick</surname><given-names>S</given-names></name><name><surname>Hodgson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><issue>6</issue><fpage>2264</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1577</pub-id><?supplied-pmid 20215513?><pub-id pub-id-type="pmid">20215513</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loboda</surname><given-names>A</given-names></name><name><surname>Nebozhyn</surname><given-names>M</given-names></name><name><surname>Klinghoffer</surname><given-names>R</given-names></name><name><surname>Frazier</surname><given-names>J</given-names></name><name><surname>Chastain</surname><given-names>M</given-names></name><name><surname>Arthur</surname><given-names>W</given-names></name><etal/></person-group><article-title>A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors</article-title><source>BMC Med Genomics</source><year>2010</year><volume>3</volume><fpage>26</fpage><pub-id pub-id-type="doi">10.1186/1755-8794-3-26</pub-id><?supplied-pmid 20591134?><pub-id pub-id-type="pmid">20591134</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cancer Genome Atlas</surname><given-names>N</given-names></name></person-group><article-title>Comprehensive molecular characterization of human colon and rectal cancer</article-title><source>Nature</source><year>2012</year><volume>487</volume><issue>7407</issue><fpage>330</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/nature11252</pub-id><pub-id pub-id-type="pmid">22810696</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malapelle</surname><given-names>U</given-names></name><name><surname>Carlomagno</surname><given-names>C</given-names></name><name><surname>de Luca</surname><given-names>C</given-names></name><name><surname>Bellevicine</surname><given-names>C</given-names></name><name><surname>Troncone</surname><given-names>G</given-names></name></person-group><article-title>KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond</article-title><source>J Clin Pathol</source><year>2014</year><volume>67</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1136/jclinpath-2013-201835</pub-id><?supplied-pmid 24022727?><pub-id pub-id-type="pmid">24022727</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciardiello</surname><given-names>F</given-names></name><name><surname>Tortora</surname><given-names>G</given-names></name></person-group><article-title>EGFR antagonists in cancer treatment</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><issue>11</issue><fpage>1160</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1056/NEJMra0707704</pub-id><?supplied-pmid 18337605?><pub-id pub-id-type="pmid">18337605</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Roock</surname><given-names>W</given-names></name><name><surname>Claes</surname><given-names>B</given-names></name><name><surname>Bernasconi</surname><given-names>D</given-names></name><name><surname>De Schutter</surname><given-names>J</given-names></name><name><surname>Biesmans</surname><given-names>B</given-names></name><name><surname>Fountzilas</surname><given-names>G</given-names></name><etal/></person-group><article-title>Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis</article-title><source>Lancet Oncol</source><year>2010</year><volume>11</volume><issue>8</issue><fpage>753</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(10)70130-3</pub-id><?supplied-pmid 20619739?><pub-id pub-id-type="pmid">20619739</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeatman</surname><given-names>TJ</given-names></name></person-group><article-title>Predictive biomarkers: identification and verification</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>17</issue><fpage>2743</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.21.5087</pub-id><?supplied-pmid 19332709?><pub-id pub-id-type="pmid">19332709</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bronte</surname><given-names>G</given-names></name><name><surname>Silvestris</surname><given-names>N</given-names></name><name><surname>Castiglia</surname><given-names>M</given-names></name><name><surname>Galvano</surname><given-names>A</given-names></name><name><surname>Passiglia</surname><given-names>F</given-names></name><name><surname>Sortino</surname><given-names>G</given-names></name><etal/></person-group><article-title>New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><issue>28</issue><fpage>24780</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.4959</pub-id><?supplied-pmid 26318427?><pub-id pub-id-type="pmid">26318427</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Oliner</surname><given-names>KS</given-names></name><name><surname>Siena</surname><given-names>S</given-names></name><name><surname>Tabernero</surname><given-names>J</given-names></name><name><surname>Burkes</surname><given-names>R</given-names></name><name><surname>Barugel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>11</issue><fpage>1023</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1305275</pub-id><?supplied-pmid 24024839?><pub-id pub-id-type="pmid">24024839</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guinney</surname><given-names>J</given-names></name><name><surname>Ferte</surname><given-names>C</given-names></name><name><surname>Dry</surname><given-names>J</given-names></name><name><surname>McEwen</surname><given-names>R</given-names></name><name><surname>Manceau</surname><given-names>G</given-names></name><name><surname>Kao</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients</article-title><source>Clin Cancer Res</source><year>2014</year><volume>20</volume><issue>1</issue><fpage>265</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-1943</pub-id><?supplied-pmid 24170544?><pub-id pub-id-type="pmid">24170544</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laurent-Puig</surname><given-names>P</given-names></name><name><surname>Cayre</surname><given-names>A</given-names></name><name><surname>Manceau</surname><given-names>G</given-names></name><name><surname>Buc</surname><given-names>E</given-names></name><name><surname>Bachet</surname><given-names>JB</given-names></name><name><surname>Lecomte</surname><given-names>T</given-names></name><etal/></person-group><article-title>Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>35</issue><fpage>5924</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.21.6796</pub-id><?supplied-pmid 19884556?><pub-id pub-id-type="pmid">19884556</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lievre</surname><given-names>A</given-names></name><name><surname>Bachet</surname><given-names>JB</given-names></name><name><surname>Le Corre</surname><given-names>D</given-names></name><name><surname>Boige</surname><given-names>V</given-names></name><name><surname>Landi</surname><given-names>B</given-names></name><name><surname>Emile</surname><given-names>JF</given-names></name><etal/></person-group><article-title>KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><issue>8</issue><fpage>3992</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-0191</pub-id><?supplied-pmid 16618717?><pub-id pub-id-type="pmid">16618717</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loupakis</surname><given-names>F</given-names></name><name><surname>Ruzzo</surname><given-names>A</given-names></name><name><surname>Cremolini</surname><given-names>C</given-names></name><name><surname>Vincenzi</surname><given-names>B</given-names></name><name><surname>Salvatore</surname><given-names>L</given-names></name><name><surname>Santini</surname><given-names>D</given-names></name><etal/></person-group><article-title>KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer</article-title><source>Br J Cancer</source><year>2009</year><volume>101</volume><issue>4</issue><fpage>715</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605177</pub-id><?supplied-pmid 19603018?><pub-id pub-id-type="pmid">19603018</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosakhani</surname><given-names>N</given-names></name><name><surname>Lahti</surname><given-names>L</given-names></name><name><surname>Borze</surname><given-names>I</given-names></name><name><surname>Karjalainen-Lindsberg</surname><given-names>ML</given-names></name><name><surname>Sundstrom</surname><given-names>J</given-names></name><name><surname>Ristamaki</surname><given-names>R</given-names></name><etal/></person-group><article-title>MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF</article-title><source>Cancer Genet</source><year>2012</year><volume>205</volume><issue>11</issue><fpage>545</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.cancergen.2012.08.003</pub-id><?supplied-pmid 23098991?><pub-id pub-id-type="pmid">23098991</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Astolfi</surname><given-names>A</given-names></name><name><surname>Urbini</surname><given-names>M</given-names></name><name><surname>Indio</surname><given-names>V</given-names></name><name><surname>Nannini</surname><given-names>M</given-names></name><name><surname>Genovese</surname><given-names>CG</given-names></name><name><surname>Santini</surname><given-names>D</given-names></name><etal/></person-group><article-title>Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST)</article-title><source>BMC Genomics</source><year>2015</year><volume>16</volume><fpage>892</fpage><pub-id pub-id-type="doi">10.1186/s12864-015-1982-6</pub-id><?supplied-pmid 26531060?><pub-id pub-id-type="pmid">26531060</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Mustafa DA, Sieuwerts AM, Smid M, de Weerd V, van der Weiden M, Meijer-van Gelder ME, et al. A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds. PLoS One. 2015;10(12). e0144097.</mixed-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veldman-Jones</surname><given-names>MH</given-names></name><name><surname>Brant</surname><given-names>R</given-names></name><name><surname>Rooney</surname><given-names>C</given-names></name><name><surname>Geh</surname><given-names>C</given-names></name><name><surname>Emery</surname><given-names>H</given-names></name><name><surname>Harbron</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples</article-title><source>Cancer Res</source><year>2015</year><volume>75</volume><issue>13</issue><fpage>2587</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-0262</pub-id><?supplied-pmid 26069246?><pub-id pub-id-type="pmid">26069246</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sfakianos</surname><given-names>GP</given-names></name><name><surname>Iversen</surname><given-names>ES</given-names></name><name><surname>Whitaker</surname><given-names>R</given-names></name><name><surname>Akushevich</surname><given-names>L</given-names></name><name><surname>Schildkraut</surname><given-names>JM</given-names></name><name><surname>Murphy</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues</article-title><source>Gynecol Oncol</source><year>2013</year><volume>129</volume><issue>1</issue><fpage>159</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2012.12.030</pub-id><?supplied-pmid 23274563?><pub-id pub-id-type="pmid">23274563</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">von Ahlfen S, Missel A, Bendrat K, Schlumpberger M. Determinants of RNA quality from FFPE samples. PLoS One. 2007;2(12). e1261.</mixed-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Navarro</surname><given-names>I</given-names></name><name><surname>Gamez-Pozo</surname><given-names>A</given-names></name><name><surname>Gonzalez-Baron</surname><given-names>M</given-names></name><name><surname>Pinto-Marin</surname><given-names>A</given-names></name><name><surname>Hardisson</surname><given-names>D</given-names></name><name><surname>Lopez</surname><given-names>R</given-names></name><etal/></person-group><article-title>Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues</article-title><source>Biotechniques</source><year>2010</year><volume>48</volume><issue>5</issue><fpage>389</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.2144/000113388</pub-id><?supplied-pmid 20569212?><pub-id pub-id-type="pmid">20569212</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reis</surname><given-names>PP</given-names></name><name><surname>Waldron</surname><given-names>L</given-names></name><name><surname>Goswami</surname><given-names>RS</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Xuan</surname><given-names>Y</given-names></name><name><surname>Perez-Ordonez</surname><given-names>B</given-names></name><etal/></person-group><article-title>mRNA transcript quantification in archival samples using multiplexed, color-coded probes</article-title><source>BMC Biotechnol</source><year>2011</year><volume>11</volume><fpage>46</fpage><pub-id pub-id-type="doi">10.1186/1472-6750-11-46</pub-id><?supplied-pmid 21549012?><pub-id pub-id-type="pmid">21549012</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veldman-Jones</surname><given-names>MH</given-names></name><name><surname>Lai</surname><given-names>Z</given-names></name><name><surname>Wappett</surname><given-names>M</given-names></name><name><surname>Harbron</surname><given-names>CG</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Harrington</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System</article-title><source>Clin Cancer Res</source><year>2015</year><volume>21</volume><issue>10</issue><fpage>2367</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0357</pub-id><?supplied-pmid 25301847?><pub-id pub-id-type="pmid">25301847</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schell</surname><given-names>MJ</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Missiaglia</surname><given-names>E</given-names></name><name><surname>Delorenzi</surname><given-names>M</given-names></name><name><surname>Soneson</surname><given-names>C</given-names></name><name><surname>Yue</surname><given-names>B</given-names></name><etal/></person-group><article-title>A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome</article-title><source>Clin Cancer Res</source><year>2016</year><volume>22</volume><issue>3</issue><fpage>734</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-0143</pub-id><?supplied-pmid 26446941?><pub-id pub-id-type="pmid">26446941</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenstermacher</surname><given-names>DA</given-names></name><name><surname>Wenham</surname><given-names>RM</given-names></name><name><surname>Rollison</surname><given-names>DE</given-names></name><name><surname>Dalton</surname><given-names>WS</given-names></name></person-group><article-title>Implementing personalized medicine in a cancer center</article-title><source>Cancer J</source><year>2011</year><volume>17</volume><issue>6</issue><fpage>528</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1097/PPO.0b013e318238216e</pub-id><?supplied-pmid 22157297?><pub-id pub-id-type="pmid">22157297</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Hobbs</surname><given-names>B</given-names></name><name><surname>Collin</surname><given-names>F</given-names></name><name><surname>Beazer-Barclay</surname><given-names>YD</given-names></name><name><surname>Antonellis</surname><given-names>KJ</given-names></name><name><surname>Scherf</surname><given-names>U</given-names></name><etal/></person-group><article-title>Exploration, normalization, and summaries of high density oligonucleotide array probe level data</article-title><source>Biostatistics</source><year>2003</year><volume>4</volume><issue>2</issue><fpage>249</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1093/biostatistics/4.2.249</pub-id><?supplied-pmid 12925520?><pub-id pub-id-type="pmid">12925520</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilsenbeck</surname><given-names>SG</given-names></name><name><surname>Friedrichs</surname><given-names>WE</given-names></name><name><surname>Schiff</surname><given-names>R</given-names></name><name><surname>O'Connell</surname><given-names>P</given-names></name><name><surname>Hansen</surname><given-names>RK</given-names></name><name><surname>Osborne</surname><given-names>CK</given-names></name><etal/></person-group><article-title>Statistical analysis of array expression data as applied to the problem of tamoxifen resistance</article-title><source>J Natl Cancer Inst</source><year>1999</year><volume>91</volume><issue>5</issue><fpage>453</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/jnci/91.5.453</pub-id><?supplied-pmid 10070945?><pub-id pub-id-type="pmid">10070945</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>RM</given-names></name></person-group><source>Design and analysis of DNA microarray investigations</source><year>2003</year><publisher-loc>New York</publisher-loc><publisher-name>Springer</publisher-name><fpage>199</fpage></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><article-title>Differential expression analysis for sequence count data</article-title><source>Genome Biol</source><year>2010</year><volume>11</volume><issue>10</issue><fpage>R106</fpage><pub-id pub-id-type="doi">10.1186/gb-2010-11-10-r106</pub-id><?supplied-pmid 20979621?><pub-id pub-id-type="pmid">20979621</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><etal/></person-group><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><year>2013</year><volume>29</volume><issue>1</issue><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><?supplied-pmid 23104886?><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Goff</surname><given-names>L</given-names></name><name><surname>Pertea</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Kelley</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks</article-title><source>Nat Protoc</source><year>2012</year><volume>7</volume><issue>3</issue><fpage>562</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1038/nprot.2012.016</pub-id><?supplied-pmid 22383036?><pub-id pub-id-type="pmid">22383036</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>R</given-names></name><name><surname>Lam</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>MC</given-names></name><name><surname>Ngan</surname><given-names>M</given-names></name><name><surname>Menenzes</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>Analysis of gene expression data using BRB-ArrayTools</article-title><source>Cancer informatics</source><year>2007</year><volume>3</volume><fpage>11</fpage><lpage>7</lpage><?supplied-pmid 19455231?><pub-id pub-id-type="pmid">19455231</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Narasimhan</surname><given-names>B</given-names></name><name><surname>Chu</surname><given-names>G</given-names></name></person-group><article-title>Diagnosis of multiple cancer types by shrunken centroids of gene expression</article-title><source>Proc Natl Acad Sci U S A</source><year>2002</year><volume>99</volume><issue>10</issue><fpage>6567</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1073/pnas.082099299</pub-id><?supplied-pmid 12011421?><pub-id pub-id-type="pmid">12011421</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>R</given-names></name><name><surname>Radmacher</surname><given-names>MD</given-names></name><name><surname>Dobbin</surname><given-names>K</given-names></name><name><surname>McShane</surname><given-names>LM</given-names></name></person-group><article-title>Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification</article-title><source>J Natl Cancer Inst</source><year>2003</year><volume>95</volume><issue>1</issue><fpage>14</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/jnci/95.1.14</pub-id><?supplied-pmid 12509396?><pub-id pub-id-type="pmid">12509396</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bresters</surname><given-names>D</given-names></name><name><surname>Schipper</surname><given-names>ME</given-names></name><name><surname>Reesink</surname><given-names>HW</given-names></name><name><surname>Boeser-Nunnink</surname><given-names>BD</given-names></name><name><surname>Cuypers</surname><given-names>HT</given-names></name></person-group><article-title>The duration of fixation influences the yield of HCV cDNA-PCR products from formalin-fixed, paraffin-embedded liver tissue</article-title><source>J Virol Methods</source><year>1994</year><volume>48</volume><issue>2&#x02013;3</issue><fpage>267</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/0166-0934(94)90125-2</pub-id><?supplied-pmid 7989443?><pub-id pub-id-type="pmid">7989443</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Lebbe C, Guedj M, Basset-Seguin N, Podgorniak MP, Menashi S, Janin A, et al. A reliable method for the selection of exploitable melanoma archival paraffin embedded tissues for transcript biomarker profiling. PLoS One. 2012;7(1). e29143.</mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Mittempergher L, de Ronde JJ, Nieuwland M, Kerkhoven RM, Simon I, Rutgers EJ, et al. Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS One. 2011;6(2). e17163.</mixed-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farragher</surname><given-names>SM</given-names></name><name><surname>Tanney</surname><given-names>A</given-names></name><name><surname>Kennedy</surname><given-names>RD</given-names></name><name><surname>Paul</surname><given-names>HD</given-names></name></person-group><article-title>RNA expression analysis from formalin fixed paraffin embedded tissues</article-title><source>Histochem Cell Biol</source><year>2008</year><volume>130</volume><issue>3</issue><fpage>435</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1007/s00418-008-0479-7</pub-id><?supplied-pmid 18679706?><pub-id pub-id-type="pmid">18679706</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hackstadt</surname><given-names>AJ</given-names></name><name><surname>Hess</surname><given-names>AM</given-names></name></person-group><article-title>Filtering for increased power for microarray data analysis</article-title><source>BMC Bioinformatics</source><year>2009</year><volume>10</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-10-11</pub-id><?supplied-pmid 19133141?><pub-id pub-id-type="pmid">19133141</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Scott</surname><given-names>DA</given-names></name><name><surname>Hatch</surname><given-names>E</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Mansour</surname><given-names>SL</given-names></name></person-group><article-title>Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development</article-title><source>Development</source><year>2007</year><volume>134</volume><issue>1</issue><fpage>167</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1242/dev.02701</pub-id><?supplied-pmid 17164422?><pub-id pub-id-type="pmid">17164422</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oberst</surname><given-names>MD</given-names></name><name><surname>Beberman</surname><given-names>SJ</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Yin</surname><given-names>JJ</given-names></name><name><surname>Ward</surname><given-names>Y</given-names></name><name><surname>Kelly</surname><given-names>K</given-names></name></person-group><article-title>TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation</article-title><source>BMC Cancer</source><year>2008</year><volume>8</volume><fpage>189</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-8-189</pub-id><?supplied-pmid 18597688?><pub-id pub-id-type="pmid">18597688</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollenhorst</surname><given-names>PC</given-names></name><name><surname>Ferris</surname><given-names>MW</given-names></name><name><surname>Hull</surname><given-names>MA</given-names></name><name><surname>Chae</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Graves</surname><given-names>BJ</given-names></name></person-group><article-title>Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells</article-title><source>Genes Dev</source><year>2011</year><volume>25</volume><issue>20</issue><fpage>2147</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1101/gad.17546311</pub-id><?supplied-pmid 22012618?><pub-id pub-id-type="pmid">22012618</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiss-Toth</surname><given-names>E</given-names></name><name><surname>Bagstaff</surname><given-names>SM</given-names></name><name><surname>Sung</surname><given-names>HY</given-names></name><name><surname>Jozsa</surname><given-names>V</given-names></name><name><surname>Dempsey</surname><given-names>C</given-names></name><name><surname>Caunt</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Human tribbles, a protein family controlling mitogen-activated protein kinase cascades</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><issue>41</issue><fpage>42703</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1074/jbc.M407732200</pub-id><?supplied-pmid 15299019?><pub-id pub-id-type="pmid">15299019</pub-id></element-citation></ref></ref-list></back></article>